Jordi E. R.
- Country
- Spain
- Department
- 172412: Hematología
Research Overview
- Phase I Evaluation of BMS-986497 Monotherapy and in Combination with Azacitidine and Azacitidine Plus Venetoclax in Relapsed/Refractory AML or MDS
- A Phase I First-in-Human Study to Evaluate the Safety and Pharmacokinetics of GEN3018 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- Phase 3 Study of Oral Arsenic Trioxide QTX-2101 in Newly Diagnosed Low-Risk Acute Promyelocytic Leukemia
Data & Insights
Has run more than one trial at 209 of 339 partner sites.
Specializations
Acute Myeloid Leukemia
This investigator specializes in treating relapsed and refractory acute myeloid leukemia (AML), with particular focus on novel therapeutic approaches for patients who have not responded to conventional treatments.
- KMT2A/MLL gene alterations
- NPM1 mutations
- Post-transplant maintenance therapy
Their research extends to investigating innovative treatment combinations and targeted therapies for specific genetic mutations in AML.
Myelodysplastic Conditions
The investigator conducts research in high-risk myelodysplastic syndromes (MDS) and related conditions, focusing on developing treatment strategies for challenging cases.
- Higher-risk MDS
- Chronic Myelomonocytic Leukemia
- Myelodysplastic neoplasms
Their work includes evaluating novel therapeutic agents for patients with advanced myeloid disorders.
Lymphoid Malignancies
The investigator's expertise includes treating acute lymphoid leukemia (ALL), with specific emphasis on innovative cellular therapies and targeted treatments.
- CD19-positive leukemia
- Refractory lymphoid conditions
- Cellular therapy approaches
Their research encompasses developing new therapeutic strategies for resistant and refractory lymphoid malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.